Pharma Two B

Pharma Two B Ltd. is a specialty pharmaceuticals company based in Rehovot, Israel, with a subsidiary in the United States. Founded in 2007, the company focuses on developing clinically differentiated and value-added products based on approved drugs, particularly through fixed-dose combinations (FDCs) that feature two or more drugs with complementary effects. Its primary therapeutic areas of interest are Parkinson's disease and various types of cancer, including pancreatic, lung, and breast cancer. Pharma Two B aims to address significant unmet medical needs by utilizing a US 505b2 regulatory approach, which facilitates shorter approval timelines. The company also develops generic products with non-infringing formulations and licenses these products for development and commercialization through milestone and royalty arrangements.